Oral Misoprostol for Outpatient Induction of Labor

NCT ID: NCT04596397

Last Updated: 2021-04-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-16
• Study Completion Date: 2021-03-25

Brief Summary

An increasing proportion of pregnant women have their labors induced due to changing guidelines. In correlation with this increase, the population of the induced women has changed toward more women with a low-risk pregnancy. Traditionally, induction of labor has taken place in an inpatient setting where the women have spent extra days in hospital before delivery.

Oral prostaglandins, such as misoprostol, is one of the most commonly used induction agent and is easy for the pregnant women to administrate. The pharmacological effect is ripening the cervix and compared to the mechanical cervical ripening, with a balloon catheter, the demands on busy maternity services seems reduced. Before contractions start, the risk of adverse effects on mother or fetus is considered low, but the evidence on use of misoprostol in an outpatient setting is sparse.

Detailed Description

The implementation of induction of labor in outpatient settings is increasing despite insufficient evidence regarding safety and effectiveness. The use of a balloon catheter in an outpatient setting is not associated with adverse outcomes in a low-risk population. There is also evidence that outpatient vs inpatient induction of labor with balloon catheter is equally effective. Examination of vaginal dinoprostone (prostaglandin E2) is found to be efficacious in outpatient settings. However, strong evidence concludes that the oral route of administration of prostaglandin is preferable when inducing labor. The World Health Organization recommend 25ug misoprostol (prostaglandin E1) orally every 2 hour until contractions start for induction of labor.

The women randomized to an inpatient setting will receive the hospital standard follow-up; oral misoprostol 25ug every two hours and a cardiotocography for fetal monitoring every 4-6 hour until start of contractions for two days.

The women randomized to an outpatient setting will receive one oral misoprostol 25ug at the maternity unit. After two hours, provided a normal cardiotocography and no contractions, they can go home. They will continue to take 25ug misoprostol every two hours until start of contractions or increasing pain. Maximum time spent at home will be 48 hours.

A dedicated midwife on call will always be available for questions. The women will receive oral and written information to return to the maternity unit if the water breaks, if they experience increasing pain or bleeding, if they feel insecure or anxious, if there are reduced or no fetal movements, and/or when the contraction starts. When the woman returns, she will stay admitted until delivery.

All women will be given standard of care and fetal surveillance when admitted to the hospital, when the contractions start or if the contractions are still absent after 48 hours. We will also ask eligible women who refrain to participate about their reasons for non-participation.

PRIMARY RESEARCH QUESTION We aim to explore that induction of labor using oral misoprostol appears feasible in an outpatient setting and may positively influence the length of the hospital stay and maternal satisfaction.

PRIMARY RESEARCH PLAN This is a pilot study to explore the feasibility of a possible multicenter randomized controlled trail.

Conditions

Labor Induction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Induction of labour with oral misoprostol, inpatient setting

These women receive all treatment in the maternity unit.

Group Type: ACTIVE_COMPARATOR

Inpatient setting

Intervention Type: OTHER

These women stay at the hospital.

Induction of labour with oral misoprostol, outpatient setting

These women will be observed 2 hours after they receive one dose of oral misoprostol before the can leave the maternity unit.

Group Type: EXPERIMENTAL

Outpatient setting

Intervention Type: OTHER

These women can leave the hospital.

Interventions

Inpatient setting

These women stay at the hospital.

Intervention Type: OTHER

Outpatient setting

These women can leave the hospital.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Understand and read Norwegian
• No cognitive barriers. The woman must be able to give informed consent
• ≥ 37 gestational week, vertex presentation, single pregnancy
• Normal ultrasound including fetal movements, amniotic fluid, estimated fetal weight +/- 15% (≤ 10 percentile and ≥ 90) and normal doppler peak systolic index in the umbilical cord artery and the cerebri media artery
• Normal cardiotocography
• Body Mass Index 18-35
• No signs of infection or health problems
• Distance to hospital 45-60 minutes

Exclusion Criteria

• Premature rupture of membranes
• Previous cesarean section or operation on uterus
• Fetal anomaly or chromosome/genetic disorder
• Pregnancy complications such as preeclampsia and diabetes (insulin dependent) or other conditions were changes in fetal heart rate during labor is suspected
• Not eligible for misoprostol as induction agent due a favorable cervix (Bishop score) and/or previous obstetric history

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Sorlandet Hospital HF

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janne Rossen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Sorlandet Hospital Trust, Kristiansand, Norway

Locations

Sorlandet Hospital Trust

Kristiansand, , Norway

Countries

Norway

References

Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, Alfirevic Z. Pharmacological and mechanical interventions for labour induction in outpatient settings. Cochrane Database Syst Rev. 2017 Sep 13;9(9):CD007701. doi: 10.1002/14651858.CD007701.pub3.

Reference Type: BACKGROUND

PMID: 28901007 (View on PubMed)

Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev. 2014 Jun 13;2014(6):CD001338. doi: 10.1002/14651858.CD001338.pub3.

Reference Type: BACKGROUND

PMID: 24924489 (View on PubMed)

WHO Recommendations for Induction of Labour. Geneva: World Health Organization; 2011. Available from http://www.ncbi.nlm.nih.gov/books/NBK131963/

Reference Type: BACKGROUND

PMID: 23586118 (View on PubMed)

Diederen M, Gommers J, Wilkinson C, Turnbull D, Mol B. Safety of the balloon catheter for cervical ripening in outpatient care: complications during the period from insertion to expulsion of a balloon catheter in the process of labour induction: a systematic review. BJOG. 2018 Aug;125(9):1086-1095. doi: 10.1111/1471-0528.15047. Epub 2018 Jan 10.

Reference Type: BACKGROUND

PMID: 29211328 (View on PubMed)

Wilkinson C, Bryce R, Adelson P, Turnbull D. A randomised controlled trial of outpatient compared with inpatient cervical ripening with prostaglandin E(2) (OPRA study). BJOG. 2015 Jan;122(1):94-104. doi: 10.1111/1471-0528.12846. Epub 2014 May 14.

Reference Type: BACKGROUND

PMID: 24824157 (View on PubMed)

Other Identifiers

2020/104044

Identifier Type: -

Identifier Source: org_study_id